In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

Companies like AstraZeneca and GSK, which have high-revenue-generating inhalers for asthma and chronic obstructive pulmonary ...

Though prescribing climate-friendly dry powder inhalers is environmentally sound, some experts warn certain patients may be ...

GlaxoSmithKline, and Novartis. According to TipRanks, Welford has an average return of 4.4% and a 52.89% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy ...

“If the GSK saga is a good parallel, then AstraZeneca’s China business could be in for retraction over the next 1-2 years,” ...

The firm's commentary highlighted the ongoing investigation into certain AstraZeneca employees in China, drawing comparisons to a similar situation faced by GlaxoSmithKline (NYSE:GSK) over a ...

The firm's commentary highlighted the ongoing investigation into certain AstraZeneca employees in China, drawing comparisons to a similar situation faced by GlaxoSmithKline (NYSE:GSK) over a decade ...

What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...

With an array of new medicines and medical devices on display global medical companies are looking to tap further into the ...

DelveInsight's 'Severe Asthma Pipeline Insight 2024' report provides comprehensive global coverage of pipeline severe asthma ...

"China market is one of the most attractive markets for Edwards," said Leo Tam, senior director of the business unit of Transcatheter Aortic Valve Replacement, Edwards Lifesciences China, citing a lot ...